İsrail - İbranice - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

İsrail - İbranice - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation 250 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

İsrail - İbranice - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation vhsd treated 500 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

İsrail - İbranice - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation 1000 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

İsrail - İbranice - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

İsrail - İbranice - Ministry of Health

ferring pharmaceuticals ltd - urofollitrophin highly purified (hpfsh) 75 iu/vial - powder for solution for injection - urofollitropin - anovulation (including polycystis ovarian disease (pcod) in women who have been unresponsive to treatment with clomiphene citrate. controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (art) (e.g. in vitro fertilisation/embryo transfer (evf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)).

İsrail - İbranice - Ministry of Health

vitamed ltd,binyamina - piperacillin as sodium 4 g/vial - powder for solution for injection - piperacillin - for the treatment and prophylaxis of systemic and local infections due to susceptible gram (-) and gram ( +) aerobic and anaerobic bacteria.

İsrail - İbranice - Ministry of Health

vitamed ltd,binyamina - cefazolin sodium 1000 mg/vial - powder for solution for injection - cefazolin - kefazin is indicated for the treatment of infections due to susceptible organisms.

İsrail - İbranice - Ministry of Health

masrouji company ltd - cefazolin as sodium 500 mg/vial - powder for solution for injection - cefazolin - treatment of serious infections caused by susceptible organisms and also perioperatively for prophylaxis. treatment respiratory tract: respiratory tract infections due to streptococcus pneumoniae (formerly diplococcus pneumoniae) klebsiella species haemophilus influenzae staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group a b - hemolytic streptococci. cefazolin is effective in the eradication of streptococci from the nasopharynx. however data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. urinary tract: infections due to escherichia coli klebsiella species proteus mirabilis and some strains of enterobacter and enterococci. skin and skin structure: -hemolytic beta infections due to staphylococcus aureus (penicillin-sensitive and penicillin-resistant) group a streptococci and other strains of streptococci. biliary tract: infections due to escherichia coli various strains of streptococci proteus mirabilis klebsiella

İsrail - İbranice - Ministry of Health

vitamed ltd,binyamina - cefuroxime as sodium 750 mg/vial - powder for solution for injection - cefuroxime - for the treatment of diseases caused by micro-organisms sensitive to cefuroxime.